Water Flow-Like Algorithm with Simulated Annealing for Travelling Salesman Problems

Water Flow-like Algorithm (WFA) has been proved its ability obtaining a fast and quality solution for solving Travelling Salesman Problem (TSP). The WFA uses the insertion move with 2-neighbourhood search to get better flow splitting and moving decision. However, the algorithms can be improved by making a good balance between its solution search exploitation and exploration. Such improvement can be achieved by hybridizing good search algorithm with WFA.  This paper presents a hybrid of WFA with various three neighbourhood search in Simulated Annealing (SA) for TSP problem. The performance of the proposed method is evaluated using 18 large TSP benchmark datasets. The experimental result shows that the hybrid method has improved the solution quality compare with the basic WFA and state of art algorithm for TSP

Some recent studies on hohlraum physics

Some of our recent studies on hohlraum physics are presented, mainly including simulation study on hohlraum physics experiments on SGIII prototype, the design of Au + U + Au sandwich hohlraum for ignition target, and an initial design of elliptical hohlraum and pertinent drive laser power in order to generate an ignition radiation profile

Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial

Background: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. Patients and Methods: The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate >= 25 mL/min/1.73 m(2) and albuminuria (urinary albumin-to-creatinine ratio >= 30 to <= 5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level alpha = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. Conclusions: FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049

Some recent studies on hohlraum physics

Some of our recent studies on hohlraum physics are presented, mainly including simulation study on hohlraum physics experiments on SGIII prototype, the design of Au + U + Au sandwich hohlraum for ignition target, and an initial design of elliptical hohlraum and pertinent drive laser power in order to generate an ignition radiation profile